Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus

This publication has 21 references indexed in Scilit:

• Putting Insulin Glargine and Malignancies into Perspective
  The Oncologist, 2009
• Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study
  Diabetologia, 2009
• Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis
  The American Journal of the Medical Sciences, 2009
• A Nationwide Survey about the Current Status of Glycemic Control and Complications in Diabetic Patients in 2006 - The Committee of the Korean Diabetes Association on the Epidemiology of Diabetes Mellitus -
  Korean Diabetes Journal, 2009
• Staged diabetes management according to individual patient insulin resistance and β‐cell function ameliorates glycaemic control in type 2 diabetes mellitus
  Clinical Endocrinology, 2008
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial
  Diabetes, Obesity and Metabolism, 2007
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
  Diabetologia, 2006
• Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes
  Diabetes, 2006
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
  The Lancet, 1998
• Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial
  The American Journal of Cardiology, 1995